32^nd European Neurology Congress

Varicella- zoster virus (VZV) is an exclusively human neurotropic, double-stranded DNA alpha herpesvirus, primary infection causes varicella (chickenpox), with a decline in VZV-specific cell-mediated immunity in elderly and immunocompromised individuals and VZV reactivates to cause herpes zoster (shingles) with its complications. Varicella-zoster virus infections can produce multiple disorders of the central and peripheral nervous system and often without rash. The most common complication of herpes zoster is post herpetic neuralgia, pain that persists months to years after rash resolved. Herpes zoster may cause serious chronic complications, including PHN, cerebral arteritis and herpes zoster ophthalmicus. The important of early diagnosis with a rapid virology verification and early prompt treatment with antiviral agents can lead to complete recovery; even in patients with protracted disease. Herpes zoster vaccination significantly reduces the incidence of both Herpes zoster, post herpetic neuralgia and other complications. Given the limitations of existing zoster therapies, the prevention of VZV infection has gained overriding importance. VZV vaccinations can reduce both the health and economic eff ects of Herpes zoster. Although relatively costly, vaccinations not only reduce the risk of infection but may also preserve healthrelated QOL in the geriatric population. With seven cases studies presentation there will be a high light on different Varicella- zoster clinical presentations.